Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer

Joshua D. Palmer, Nicholas Zaorsky, Matthew Witek, Bo Lu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.

Original languageEnglish (US)
Pages (from-to)387-398
Number of pages12
JournalJournal of Thoracic Disease
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lung Neoplasms
Radiation
Epidermal Growth Factor Receptor
Genes
Neoplasms
Therapeutics
Biomarkers
Research Personnel
Medicine
Clinical Trials
Inflammation
Mutation
Research
Population

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

@article{c7633cd92888470f8a01620dba07242f,
title = "Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer",
abstract = "The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.",
author = "Palmer, {Joshua D.} and Nicholas Zaorsky and Matthew Witek and Bo Lu",
year = "2014",
month = "1",
day = "1",
doi = "10.3978/j.issn.2072-1439.2013.12.04",
language = "English (US)",
volume = "6",
pages = "387--398",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "4",

}

Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. / Palmer, Joshua D.; Zaorsky, Nicholas; Witek, Matthew; Lu, Bo.

In: Journal of Thoracic Disease, Vol. 6, No. 4, 01.01.2014, p. 387-398.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer

AU - Palmer, Joshua D.

AU - Zaorsky, Nicholas

AU - Witek, Matthew

AU - Lu, Bo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.

AB - The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84900498863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900498863&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2072-1439.2013.12.04

DO - 10.3978/j.issn.2072-1439.2013.12.04

M3 - Article

AN - SCOPUS:84900498863

VL - 6

SP - 387

EP - 398

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 4

ER -